Accuray Incorporated·Healthcare

MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026.

Accuray Incorporated (NASDAQ: ARAY - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 6,598,752 shares, a growth of 20.6% from the February 26th total of 5,471,116 shares. Approximately 5.8% of the shares of the company are sold

Accuray (NASDAQ: ARAY) executives used the company's fiscal second-quarter earnings call to outline progress on a broad transformation program while acknowledging that tariff impacts and geopolitical instability-particularly in China-pressured results and prompted a reset of full-year guidance. Transformation plan targets profitability and operational discipline CEO Steve La Neve said the company is executing a "comprehensive strategic,

Accuray Incorporated (ARAY) Q2 2026 Earnings Call Transcript

MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2025.

Acuitas Investments LLC increased its position in shares of Accuray Incorporated (NASDAQ: ARAY) by 67.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,392,126 shares of the medical equipment provider's stock after acquiring an additional 966,100 shares during the quarter.
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Healthcare
Medical - Devices
987
2007-02-08
1.32